Agreement with Biotronik Australia Pty Limited for the supply of interventional cardiology devices
PHARMAC is pleased to announce the approval of an agreement with Biotronik Australia Pty Limited (“Biotronik”) for the supply of interventional cardiology devices.
In summary, the effect of the decision is that:
- A range of 288 interventional cardiology devices (guide wires, cutting balloon catheters, dilatation balloon catheters, drug eluting balloon catheters, bare metal stents, drug eluting stents and covered stents) will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 July 2016.
- DHB hospitals can purchase these items either directly from Biotronik or through a designated third party logistics provider under the national agreement.
- There are estimated savings to DHBs that currently use these products of approximately $82,000 per annum nationally, based on current usage.
Details of the decision
Following a Registration of Interest document issued in April 2014, PHARMAC has entered into an agreement with Biotronik for the supply of a selection of interventional cardiology devices to be listed on the Pharmaceutical Schedule. This is one of eleven PHARMAC contracts in the Interventional Cardiology category. This means that DHB hospitals may purchase these products under the national agreement at the new pricing.
The agreement is not exclusive. DHBs can continue to purchase other brands of interventional cardiology devices at their discretion. DHBs purchasing Biotronik products will do so under this agreement from 1 July 2016.
Educational services will be provided by Biotronik to DHB personnel on appropriate use of its interventional cardiology devices and will be arranged in a format and at times as agreed with individual DHBs.
PHARMAC appreciates all of the feedback that it has received and acknowledges the time people took to respond. All consultation responses received by 3 June 2016 were considered in their entirety in making a decision on the proposed changes. No concerns were raised regarding the proposals.
A summary of the feedback received is provided in the table below:
The technical aspects of the Biotronik stents were not favoured in a clinical review by one DHB.
Biotronik stents are used by a number of DHBs in New Zealand that are comfortable with the quality of the devices. DHBs are able to choose which stents best meet their requirements.
If you have any questions about this decision you can email PHARMAC at firstname.lastname@example.org or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.